Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Recs

0
Player Avatar MalibuGuru (64.44) Submitted: 12/9/2008 5:08:54 PM : Outperform Start Price: $24.40 EBS Score: -93.87

Emergent BioSolutions maintains a large economic moat through it's Biothrax vaccine. Two of it's vaccines in late stage development, a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, uniquely positions EBS to take advantage of the expected huge growth of demand in LDC and MDC.

Featured Broker Partners


Advertisement